医学
耐受性
内科学
中性粒细胞减少症
肺癌
不利影响
恶心
胃肠病学
癌症
肿瘤科
药理学
化疗
作者
David E. Gerber,Jeffrey R. Infante,Michael S. Gordon,Sarah B. Goldberg,Miguel Martín,Enriqueta Felip,Maria Martinez‐García,Joan H. Schiller,David R. Spigel,Julie Cordova,Valerie Westcott,Yulei Wang,David S. Shames,YounJeong Choi,Robert S. Kahn,Randall Dere,Divya Samineni,Jian Xu,Kedan Lin,Katie Wood
标识
DOI:10.1158/1078-0432.ccr-18-3965
摘要
LIFA exhibited dose-proportional pharmacokinetics and an acceptable safety profile, with encouraging activity in patients with PROC at the single-agent RP2D of 2.4 mg/kg.
科研通智能强力驱动
Strongly Powered by AbleSci AI